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Clinical trialsAmyotrophic lateral sclerosis (ALS) is characterized by the selective death of motor neurons in the motor cortex,
brainstem and spinal cord. It is a neurodegenerative disorder with high genetic and phenotypic variability. In
most patients, the cause of the disease is unknown. Until now, no treatment strategy has been discovered with
the exception of riluzole which has a moderate effect on the disease process. While developing a new causal
therapy targeting a speciﬁc disease-causing gene can have a huge effect on the disease process, only a limited
number of ALS patients will beneﬁt from such a therapy. Alternatively, pathogenic processes that are common
in ALS patients with different etiology can also be targeted. The effect of such a modifying treatment will be
smaller, but the target populationwill be larger asmore ALS patients could beneﬁt. In this review, we summarize
the evidence for the involvement of different biological processes in the pathogenesis of ALS andwill discuss how
strategies inﬂuencing these processes can be translated into new therapeutic approaches. In order to further
improve this translational step, there is an urgent need for a better understanding of the underlying
mechanism(s), for new ALS animal models and for rigorous protocols to perform preclinical studies.
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Amyotrophic lateral sclerosis (ALS) is an adult-onset neurodegener-
ative disorder characterized by selective motor neuron death. Both
upper motor neurons in the motor cortex and lower motor neurons in
the brainstem and in the ventral horn of the spinal cord are affected.
Patients develop a progressive muscle phenotype characterized by
spasticity, hyperreﬂexia, fasciculations, muscle atrophy and paralysis.
ALS is usually fatal within 3 to 5 years after the diagnosis (Cudkowicz
et al., 1997).
In most cases (~90%), there is no family history of ALS and these
patients are classiﬁed as sporadic ALS (SALS) patients. However, a
clear family history is present in approximately 10% of ALS patients,
and these patients suffer from familial ALS (FALS). Although the disease
is in almost all cases inherited in an autosomal dominant way, also
autosomal recessive and X-linked forms exist. Mutations in more than
10 different genes are known to cause FALS (reviewed in (Renton
et al., 2014)). The most common ones are found in the genes encoding
superoxide dismutase 1 (SOD1; ~20%), fused in sarcoma (FUS; 1-5%)
and TDP-43 (TARDBP; 1-5%). Recently, a hexanucleotide repeat
expansion (GGGGCC)n in the C9ORF72 gene was identiﬁed as the
most frequent cause of FALS (~40%) in the Western population
(DeJesus-Hernandez et al., 2011; Renton et al., 2011).
Not only genetically, but also clinically, ALS is a heterogeneous
disease. The age and site of onset, the rate of progression and the
presence and degree of cognitive dysfunction are variable. In some
patients, also neurons in theprefrontal and temporal cortex are affected.
This leads to cognitive and/or behavioral problems. These can be very
subtle, but in about 15% of ALS patients frontotemporal dementia
(FTD) is present, the main symptom of frontotemporal lobe degenera-
tion (FTLD). These patients are diagnosed as suffering from ALS-FTLD
(Lillo and Hodges, 2009; Ringholz et al., 2005). On the other hand, 15%
of FTLD patients show signs of motor neuron degeneration (Burrell
et al., 2011; Lomen-Hoerth et al., 2002). This suggests that ALS and
FTLD are at the ends of a disease spectrum. This is also reﬂected by
gene mutations that are common to both diseases (e.g. C9ORF72 and
valosin containing protein (VCP)) (Al-Chalabi et al., 2012) and by a sim-
ilar neuropathology (e.g. TDP-43 aggregates). The large variation in dis-
ease presentation is even observed in families with the same causal
gene mutation. This strongly suggests that there are factors, environ-
mental or genetic in nature, that modify the clinical phenotype of the
disease. Genetic modiﬁers of ALS are those genes that inﬂuence the se-
verity of the disease process or those that affect the risk for developing
ALS. As a consequence, these genes are very important as they could ac-
count for the clinical variability in ALS and could also play an important
role in the susceptibility for SALS.
Currently, there is no curative treatment for ALS. In 1995, riluzole
was approved by the US Food and Drug Administration (FDA) for the
treatment of ALS (Bensimon et al., 1994). Almost two decades later,
this drug remains the only approved treatment. Riluzole increases the
life span of the patients with an average of 2–3 months (Miller et al.,
2007, 2012), an effect that was reproduced in different clinical trials
(Bensimon et al., 1994, 2002; Lacomblez et al., 1996; Yanagisawa
and Shindo, 1996). As a consequence, the search for new and better
treatment strategies for ALS is a top priority. The hope is to ﬁnd
additional treatments that have cumulative effects to riluzole and that
can halt the disease process in an early state. The search for these new
treatment strategies is facilitated by the availability of good rodent
models for ALS. A number of animal models were created that faithfully
reproduce the human disease (reviewed in (McGoldrick et al., 2013)).The ﬁrst generated mouse model overexpresses the human SOD1
gene containing a substitution of glycine to alanine at position 93
(SOD1G93A) under the control of the human SOD1 promoter (Gurney
et al., 1994). This ubiquitous overexpression of human mutant SOD1
causes a progressive motor phenotype that resembles the human
disease and it is considered as the best rodentmodel so far. Extensive ef-
forts were made to generate other rodent models that recapitulate ALS,
using othermutations in the SOD1, TDP-43, or FUS gene.Whereas SOD1
mouse and rat models overexpressing different missense mutations re-
sult in an adult-onset and progressive neurodegeneration, most of the
TDP-43 and FUSmodels generated so far show an axonopathy andmus-
cle atrophy but hardly any of these show extensivemotor neuron death.
As a consequence, rodent mutant SOD1models are themost frequently
used models in translational research as these are the ones that best re-
semble clinically and pathologically the human situation.
Our expanding knowledge of both the biology of ALS and delivery
strategies for drugs in the nervous system has resulted in a number of
potential therapeutic strategies. Based on their target, these strategies
can be subdivided into two main categories: causal or modifying
treatments. While the ﬁrst type of strategies aims to directly target
disease-causing genes in order to avoid their expression and pathogenic
effects, the second one targets factors or mechanisms that inﬂuence
pathological processes related to ALS.
In this review, we will discuss a number of examples to illustrate
how strategies inﬂuencing different biological processes involved in
ALS can be translated into therapeutic approaches. We will summarize
the most promising attempts to develop causal treatment strategies,
while the main focus of this review is on the efforts to obtain
disease-modifying therapies. We will discuss the problems that arise
when potential therapeutic strategies are investigated at the preclinical
level as well as strategies that could improve the success of this transla-
tional step.
Causal treatments
Curing neurodegenerative diseases could be extremely difﬁcult
as the damage caused by the disease process seems to be irrevers-
ible. However, using a number of conditional animal models for dif-
ferent neurodegenerative diseases it has been shown that it is
possible to reverse the disease phenotype if the expression of the
mutant gene causing the disease is halted. The ﬁrst evidence was
published in 2000 by Yamamoto et al. using a mouse model of
Huntington’s disease using a tetracycline-controlled system
(Yamamoto et al., 2000). Turning off the expression of the mutated
transgene after disease onset resulted in an almost complete rever-
sal of the disease phenotype as well as in the clearance of the aggre-
gates that are the histopathological hallmark of the disease
(Yamamoto et al., 2000). Similar effects were observed in two
mouse models for different types of spinocerebellar ataxia (SCA),
SCA1 and SCA7, in which a reduction of the mutant gene expression
in symptomatic mice could halt and even reverse the disease phe-
notype (Furrer et al., 2013; Zu et al., 2004). In ALS, a partial reversal
of the motor phenotype after silencing of the transgene was ob-
served in a TDP-43 overexpressing rats. Cell-type speciﬁc overex-
pression of human mutant TDP-43 in rat, using a tetracycline-
controlled system, caused progressive paralysis with loss of motor
neurons in the ventral horn of the spinal cord (Huang et al., 2012).
Disease progression was halted and functional motor improvement
occurred after mutant gene expression was switched off (Huang
et al., 2012).
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be stopped and that symptoms can be reversed if expression of the
mutant protein is prevented. Two different strategies are used to obtain
this goal. First, expression of genes can be stopped by using gene
silencingmethods. Silencing of the SOD1 gene by using antisense oligo-
nucleotides (ASOs) or small interfering RNAs (siRNAs) is effective in
different studies using the SOD1 mouse model (Ralph et al., 2005;
Raoul et al., 2005; Rizvanov et al., 2009; Smith et al., 2006). A ﬁrst
attempt is made to translate this approach to patients. Intrathecal
delivery of SOD1 antisense oligonucleotides is in a Phase I clinical
study, and so far this seems to be well tolerated by patients (Miller
et al., 2013). Second, mutant proteins can be cleared by speciﬁcally
designed antibodies. Passive and active immunization againstmisfolded
SOD1 shows therapeutic potential in mouse models (Gros-Louis et al.,
2010; Liu et al., 2012; Urushitani et al., 2007). The generated antibodies
enhance the degradation of misfolded protein, and delay the onset and
progression of the disease in the SOD1 mouse model.
Due to the lack of animal models for the different etiologies of ALS,
causal therapies have not yet been explored for the pathogenic ALSmu-
tations in other genes. The discovery of the technique to generate
human induced pluripotent stem cells (iPSCs) (Takahashi and
Yamanaka, 2006) paves the way to model the disease caused by these
mutations in vitro (Almeida et al., 2013; Bilican et al., 2012; Dimos
et al., 2008; Donnelly et al., 2013; Egawa et al., 2012; Sareen et al.,
2013; Zhang et al., 2013b) and to explore potential causal therapies. Be-
cause of the importance of C9ORF72 repeat expansion in ALS, recent at-
tempts have mainly focused on targeting C9ORF72 transcripts by
antisense interventions (Donnelly et al., 2013; Sareen et al., 2013).Modifying treatments
The aim of modifying treatment strategies is to interfere with
pathological mechanisms that play a crucial role in the disease process,
and when targeted have a beneﬁcial effect on disease progression.
Many mechanisms have already been suggested to play a role in the
pathogenesis of ALS. These include, amongst others, astrocytosis, neuro-
inﬂammation, mitochondrial dysfunction, deregulated autophagy, and
axonal transport dysfunction and retraction. As modulating these
different disease processes could have a positive effect on disease pro-
gression, we will give an overview of these pathogenic processes, illus-
trate with some examples how these can be modiﬁed and discuss
whether these strategies have been or could be translated into new
therapies.Pathogenic role of non-neuronal cells
ALS is considered as a non-cell autonomous disorder, as expression
of mutant SOD1 exclusively in motor neurons does not seem to be suf-
ﬁcient to cause the disease (Beers et al., 2006; Gong et al., 2000; Lino
et al., 2002; Pramatarova et al., 2001). On the contrary, deletion of
mutant SOD1 in motor neurons delays disease onset, while deletion of
mutant SOD1 in astrocytes and microglia slows down disease progres-
sion (Boillee et al., 2006; Yamanaka et al., 2008). These studies suggest
that expression of mutant SOD1 in neurons is needed for the disease
to occur, and that other surrounding cells play an important role in
the neurodegeneration and especially in the progression of the disease.
Additional evidence for a role of non-neuronal cells was presented in a
study using chimeric mice with mixtures of normal and mutant SOD1
expressing cells. Mutant SOD1 containing motor neurons surrounded
by normal glial cells, showed a prolonged survival (Clement et al.,
2003). These results suggest a signiﬁcant role in the pathogenesis for
astrocytes and microglia. In addition, it was recently shown that also
oligodendrocytes play an important role in the disease process (Kang
et al., 2013).Astrocytosis
Astrocytes are glial ﬁbrillary acid protein (GFAP)-expressing
ectodermal cells that are very abundant in the nervous system and
that play an important role in supporting neuronal function. Among
others, astrocytes provide neuronswith nutrients, metabolic precursors
and trophic factors, and regulate the potassiumhomeostasis and the up-
take and catabolism of several amino acids, such as glutamate, released
by neurons (Lobsiger and Cleveland, 2007) (Fig. 1).
The speciﬁc contribution of astrocytes in ALS has been demonstrated
in vivo and in vitro. Speciﬁc deletion ofmutant SOD1 in astrocytes signif-
icantly extends survival of mutant SOD1 mice (Yamanaka et al., 2008).
Moreover, motor neuron death occurred when co-culturing mouse
embryonic stem cell-derived motor neurons with astrocytes derived
from mutant SOD1 mice (Di Giorgio et al., 2007) or post-mortem
spinal cord neural progenitor cells (NPCs) from SALS or FALS patients
(Haidet-Phillips et al., 2011).
Astrocytes acquire an activated state during disease and the number
of activated astrocytes correlates with disease progression (Hall et al.,
1998). Activated astrocytes lose their normal beneﬁcial effects
(reviewed in (Philips and Robberecht, 2011)).
On one hand, astrocytes release toxic factors and secrete reactive
oxygen and nitrogen species. Until now, the identity of these toxic
factors is largely unknown, although evidence exists for the soluble
nature of these factors. This is indicated by the fact that culturing prima-
ry motor neurons of embryonic stem cell derived motor neurons with
only the mutant astrocyte conditioned medium is toxic for the neurons
(Nagai et al., 2007). Additional efforts are necessary to elucidate the
identity of these toxic factors before this knowledge can result in new
therapeutic approaches.
On the other hand,mutant SOD1 expressing astrocytes can also fail in
protecting neurons from excitotoxicity. In patients and mutant SOD1
mice, the expression of the glial glutamate transporters is decreased
(Howland et al., 2002; Rothstein et al., 1995). In addition, astrocytes
can increase the excitability and calcium inﬂux by increasing the sodium
current or by decreasing the neuronal GluR2 expression responsible for a
higher calcium permeability of the α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) receptor, ultimately leading to neuronal
excitotoxicity (Fritz et al., 2013; Van Damme et al., 2007).
Restoring the levels of the glial glutamate transporters in astrocytes
was suggested as a possible treatment strategy (Rothstein et al., 2005).
Presymptomatic administration of ceftriaxone, a compound increasing
the expression of glial glutamate transporters in astrocytes, prolongs
survival in the mutant SOD1 mouse model (Rothstein et al., 2005). Al-
though phase I and II clinical trials were successful (Berry et al., 2013),
a phase III clinical trial investigating the effect of ceftriaxone was nega-
tive (Cudkowicz et al., 2012). Besides the restoration of intrinsic astro-
cytic properties, an enrichment of the spinal cord with healthy
astrocytes is another strategy under exploration. The focal intraspinal
administration of ‘Glial-Restricted Precursors’ (GRPs) derived from ro-
dent spinal cord attenuated motor neuron loss and extended survival
in a mutant SOD1 model (Lepore et al., 2008). Interestingly, a subse-
quent study conﬁrmed the survival and proper differentiation of
human-derived GRPs transplanted in the spinal cord of a mutant
SOD1 model (Lepore et al., 2011).Microgliosis
Microglia are ‘Cluster of Differentiation molecule 11b’ (CD11b)
expressing mesenchymal cells and are the local macrophages of the
nervous system. Using their processes, microglia constantly screen the
extracellular environment for potentially dangerous components
(reviewed in (Philips and Robberecht, 2011). These cells are in close
contact with neurons and astrocytes (Fig. 1). Microglia are actively
contributing to the disease pathogenesis, as speciﬁc deletion of mutant

















Fig. 1. Schematic presentation of physiological processes involved in normal neuromuscular functioning. 1 Involvement of non-neuronal cells: a Astrocytes are the most abundant glial
cells in the nervous system. They support neuronal function. bMicroglia are the immune cells of the nervous system. They screen the environment for hazardous substances. c Oligoden-
drocytesmyelinate the axons in the central nervous system (CNS). Moreover, these cells provide neurons with lactate which is released by themonocarboxylate transporter-1 (MCT-1). 2
Neurotrophic factors are released by several cell types in the nervous system and are required for the normal functioning of neurons. 3Mitochondria are important for energymetabolism,
intracellular calciumhomeostasis and apoptosis. 4Autophagy is one of themajor clearance pathways inneurons. It is involved in thedegradation of long-living proteins, abnormally folded
proteins and for organelle turnover.5Neurons are heavily dependent onwell-organized transportmechanisms in the long axons. 6 In the peripheral nervous system (PNS), the axon of the
motor neuron connects to the muscle at the neuromuscular junction.
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the disease process (Turner et al., 2004). The cell body enlarges and the
processes get thicker. They get properties of antigen-presenting cells
and start to interact with T-cells, which inﬁltrate in the affected spinal
cord and cortex (Alexianu et al., 2001; Engelhardt et al., 1993). This
microglial activation starts shortly before disease onset and the number
of activated glia and inﬁltrated T-cells increases with disease progres-
sion (Alexianu et al., 2001; Beers et al., 2008; Chiu et al., 2008;
Gowing et al., 2008; Hall et al., 1998). The functional alterations that
accompany these inﬂammatory events could contribute to motor
neuron death.
Reactive microglia can have two different appearances: a rather
neurotoxic one (M1 microglia) and a rather neurotrophic one (M2
microglia) (Kigerl et al., 2009). M2 microglia mainly secrete trophic
and anti-inﬂammatory factors, while M1 microglia secrete not only
pro-inﬂammatory molecules but also reactive oxygen species (ROS).
During disease progression, the microglial cell population changes
from M2 microglia to more neurotoxic M1 microglia, as was shown in
post-mortem patient material and in the mutant SOD1 mouse model
(Beers et al., 2008, 2011; Liao et al., 2012).
The appearance of either M1 or M2 microglia might depend on the
T-cell subtype that is mainly present in the spinal cord after
inﬁltration. Reciprocal signals between T-cells and microglia regulate
their appearance and phenotype (Gao and Tsirka, 2011). T-cells could
secrete different subtype-speciﬁc interleukines and cytokines
that might induce either a shift to the neuroprotective or to the neuro-
toxic state of microglia. During an early ALS phase, regulatory T (Treg)
cells are abundantly present in the spinal cord, which might maintain
microglia in an anti-inﬂammatory M2 state (Beers et al., 2011).
In later disease stages, the number of Treg cells decreases,
whereas microglia shift to a more neurotoxic state (M1) (Beers et al.,
2011). These alterations in T-cell subtypes are not only present inmouse models, but also in blood samples of ALS patients
(Beers et al., 2011; Henkel et al., 2013). All together, these data in-
dicate that subsets of T-cells can be important in disease
progression.
Different strategies that target inﬂammation have already been in-
vestigated in ALS mouse models and in patients. General immunosup-
pression or immunomodulation was ineffective (reviewed in (Philips
and Robberecht, 2011)). Administration of minocycline, a compound
that reduces microglial activation, delayed onset and prolonged the
survival in mutant SOD1 mouse models (Kriz et al., 2002; Van Den
Bosch et al., 2002; Zhu et al., 2002). However, this compound failed in
a Phase III clinical trial (Gordon et al., 2007), although questions were
raised concerning the trial design (Leigh et al., 2008). Moreover, a
later study in which SOD1 mice were treated with minocycline after
disease onset did not show a beneﬁcial effect on disease progression
(Keller et al., 2011). As most patients in clinical trials were treated
after disease onset, this could be another explanation for the negative
outcome of the minocycline trial. Celecoxib, a cyclooxygenase 2 (cox2)
inhibitor, was effective in themutant SOD1mousemodel, but not in pa-
tients (Cudkowicz et al., 2006; Drachman et al., 2002). Attempts to neu-
tralize the released ROS with vitamin E, creatine or coenzyme Q10
(CoQ10) were unsuccessful in patients (Galbussera et al., 2006;
Kaufmann et al., 2009; Shefner et al., 2004). Also the modulation of T-
cell properties and function with glatiramer acetate failed in clinical tri-
als (Meininger et al., 2009). Because of the dual nature of microglia, im-
munotherapies that suppress the neurotoxic state and retain or
promote the protective functions could form a novel strategy to treat
ALS. One possibility is a speciﬁc approach to enhance levels of Treg. A
passive transfer of early phase mutant SOD1 Treg cells prolongs the
early disease phase in SOD1 mice, by increasing M2 markers and sup-
pressing M1 markers and pro-inﬂammatory cytokines (Beers et al.,
2011).
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Oligodendrocytes are glial cells responsible for the myelination of
axons in the central nervous system (CNS). Moreover, oligodendrocytes
provide neuronal cells trophic support by the release of lactate. This
release is mediated by the monocarboxylate transporter-1 (MCT1)
(Lee et al., 2012b) (Fig. 1). It was recently shown that oligodendrocytes
play a role in neurodegeneration duringALS (Kang et al., 2013; Lee et al.,
2012b; Philips et al., 2013).While oligodendrocyte numbers remain the
same (Kang et al., 2013; Philips et al., 2013),MCT1 levels are signiﬁcant-
ly decreased in ALS patients and in ALS rodentmodels (Lee et al., 2012b;
Philips et al., 2013). In the mutant SOD1 mouse model, oligodendro-
cytes start to degenerate before disease onset and are replaced by new
oligodendrocytes that arise fromprecursor cellswith enhanced prolifer-
ation and differentiation rate, also known as NG2+ cells (Kang et al.,
2013; Magnus et al., 2008; Philips et al., 2013). These new oligodendro-
cytes have morphologic abnormalities and are not fully differentiated
(Kang et al., 2013). Moreover, expression of MCT1 and myelin basic
protein (MBP) is strongly reduced, rendering them dysfunctional in
trophic support and in myelination (Kang et al., 2013; Philips et al.,
2013). As a consequence, these new not fully mature oligodendrocytes
are not able to keep themotor neurons alive (Lee et al., 2012b). Striking-
ly, speciﬁc deletion of mutant SOD1 in the oligodendrocytes of mutant
SOD1 mice signiﬁcantly delays disease onset and survival. Disease
duration is not affected indicating that prolonged survival mainly
results from the delay in disease onset. MCT1 expression in those mice
was preserved (Kang et al., 2013). These data indicate that strategies
that induce the differentiation of NG2+ precursor cells into fully differ-
entiated oligodendrocytes could have therapeutic potential.
Altered neurotrophic support
Neurotrophic factors are naturally occurring proteins that are
essential for neuronal survival and differentiation during development.
They are also required for normal functioning of the adult nervous
system by inﬂuencing dendrite and synapse formation, proliferation,
migration and differentiation of stem cells during neurogenesis
(Fig. 1). Neurotrophic factors also play an important role in the repair
and maintenance of neurons and their axons during disease or injury
of the nervous system (Henriques et al., 2010; Suzuki and Svendsen,
2008). Increased or decreased levels of neurotrophic factors and/or
their receptors are observed in spinal cord and brain tissues of ALS
patients (Ekestern, 2004). Due to the high complexity of the system, it
is difﬁcult to deﬁne a clear pathological role for these neurotrophic
changes during ALS. However, the administration of neurotrophic fac-
tors can be an important therapeutic tool to increase the maintenance
of neurons and their connections. One example of such neurotrophic
factor that can modify ALS and that is currently tested in clinical trials
is vascular endothelial growth factor (VEGF). VEGF plays a crucial role
in the formation of new blood vessels during embryonic development
and in hypoxic conditions (reviewed in (Carmeliet and Storkebaum,
2002)). Hence, the discovery of VEGF as a modiﬁer of ALS was an unex-
pected coincidence. A transgenic mouse in which the ‘hypoxia response
element’ in the promoter region of the VEGF gene was homozygously
deleted (VEGFδ/δ mouse), revealed an important role for VEGF in the
survival of motor neurons. These mice showed reduced VEGF expres-
sion and developed motor neuron loss, muscle weakness and a func-
tional decline (Oosthuyse et al., 2001). One possible explanation for
this motor neuron degeneration is the loss of the neurotrophic effect
of VEGF (Oosthuyse et al., 2001; Van Den Bosch et al., 2004).
In addition, considerable evidence for a more speciﬁc role of VEGF in
ALS exists. The enhancement in disease severity after crossing the
VEGFδ/δ mouse with the mutant SOD1 mouse (Lambrechts et al., 2003),
the lowered VEGF expression in the spinal cords of mutant SOD1
mice before disease onset (Lu et al., 2007), the improvement of the phe-
notype when VEGF is genetically overexpressed in the same mouse
model (Wang et al., 2007) and the rescue of the mutant phenotype in azebraﬁsh model after enhancing VEGF expression (Lemmens et al.,
2007), all point towards a modifying role of VEGF in ALS. Moreover,
VEGF plays a role in the reduction of astrogliosis in the spinal cord
(Zheng et al., 2007), in the stabilization of the neuromuscular junctions
in ALS mice (Zheng et al., 2007) and in the upregulation of the GluR2
subunit of the AMPA receptor (Bogaert et al., 2010). As a consequence,
the therapeutic potential of VEGF has been extensively explored in the
mutant SOD1 rodent models. The delivery of viral vectors containing
the human VEGF transgene into the muscle or the ventricular system in-
creased the lifespan of themutant SOD1mice (Azzouz et al., 2004; Dodge
et al., 2010). Moreover, intracerebroventricular administration of VEGF
ameliorated the phenotype of ALS rats (Storkebaum et al., 2005). Finally,
injecting genetically modiﬁed stem cells secreting this neurotrophic fac-
tor in ALS mice also resulted in beneﬁcial effects (Hwang et al., 2009).
Currently, the intracerebroventricular delivery of VEGF is in a Phase I
clinical study. Other homologous compounds could be considered in
case that VEGF is not well tolerated in ALS patients, due to angiogenic
side effects. One potent alternative is VEGF-B, a structural homolog of
VEGF (Bogaert et al., 2006; Carmeliet and Storkebaum, 2002). VEGF-B
exerts similar neurotrophic effects in the mutant SOD1 mouse model,
but has onlyweak angiogenic activity. Hence, the risk for toxic side effects
is lower if a high therapeutic dose is required (Poesen et al., 2008).
Mitochondrial dysfunction
Both in animal models and in ALS patients, dysfunctional mitochon-
dria were observed. Mitochondria are multifunctional organelles
involved in ATP synthesis, intracellular calcium homeostasis, apoptosis,
etc. (Fig. 1). Hence, abnormal functioning of mitochondria can cause cell
dysfunction and subsequently cell death. In the mutant SOD1 mouse
model, swollen and vacuolated mitochondria were observed in motor
neurons and in skeletal muscle before the ﬁrst signs of motor neuron de-
generation appear (Higgins et al., 2003; Kong and Xu, 1998; Wong et al.,
1995). Similar abnormalities have been found in these tissues of sporadic
ALS patients (Aﬁﬁ et al., 1966; Sasaki and Iwata, 2007). In general, dys-
functions inmitochondrial respiration andATP synthesis, anterograde ax-
onal transport of mitochondria, mitochondrial dynamics, calcium
buffering and induction of apoptosis have all been observed in SOD1
mousemodels (reviewed in (Kawamata andManfredi, 2010)).Moreover,
these abnormalities are not restricted to mutant SOD1 pathogenesis as
also in mice overexpressing human TDP-43 abnormal distribution of mi-
tochondria and changes in mitochondrial dynamics have been described
(Wang et al., 2013; Xu et al., 2010). Although the role of other disease-
causing genes in mitochondrial dynamics has been poorly investigated,
smaller mitochondria were detected in neuronal cultures expressing
ALS-linked FUS mutants (Tradewell et al., 2012).
Because of the wide occurrence of mitochondrial dysfunction not
only in mouse models with different causal mutations but also in
sporadic patients, drugs that target these abnormalities are of therapeu-
tic interest. Dexpramipexole, olesoxime and creatine, three compounds
modulating mitochondrial function, showed promising results in
preclinical studies, but failed in clinical trials (Bordet et al., 2007;
Cudkowicz et al., 2013; Martin, 2010; Pastula et al., 2012; Shefner
et al., 2004; Sunyach et al., 2012). Currently, new strategies to improve
mitochondrial function in ALS mice are explored. These include the
inhibition of the caspase-1/cytochrome c/caspase-3 cell death pathway
through melatonin administration (Zhang et al., 2013a), disruption of
the formation of toxic complexes formed after mutant SOD1 binding
to mitochondrial proteins (Tan et al., 2013) and enhancing the mito-
chondrial calcium buffering capacity (Parone et al., 2013). These studies
seem to be promising so far.
Interestingly, peroxisome proliferator-activated receptor gamma
coactivator-1α (PGC-1α), a transcriptional co-activator that can
increase the number, the mass and the respiratory capacity of mitochon-
dria in an ALS mouse model, is also a genetic modiﬁer of ALS (Da Cruz
et al., 2012; Eschbach et al., 2013). PGC-1α orchestrates the cellular
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sis, anti-oxidative defense, angiogenesis and autophagy (Da Cruz et al.,
2012; Eschbach et al., 2013; Liang et al., 2011; Zhao et al., 2011). PGC-
1α mRNA was downregulated in the spinal cord and motor cortex of
sporadic patients as well as in mutant SOD1 mice (Thau et al., 2012). In-
terestingly, male ALS patients with a homozygous single nucleotide poly-
morphism (SNP) in the gene for PGC-1α (PPARGC1A) have an earlier
disease onset and/or a shorter disease duration (Eschbach et al., 2013).
Moreover, a full deletion of PGC-1α inmutant SOD1mice aggravated dis-
ease inmales only, with an earlier onset and faster progression (Eschbach
et al., 2013), suggesting a gender-speciﬁc loss of function of PGC-1α in
patients carrying a SNP in this gene. In line with the detrimental effect
of a loss of PGC-1α in ALS mice, a general overexpression of human
PGC-1α preservedmotor neurons and neuromuscular junctions resulting
in an increased survival of thesemice (Liang et al., 2011; Zhao et al., 2011).
These results point towards PGC-1α as an interesting therapeutic target
for ALS.
Altered autophagy
Neurodegenerative diseases are frequently characterized by the
appearance of intracellular protein aggregates that can be toxic for the
cells and by the accumulation of dysfunctional organelles, such as
mitochondria. Increasing the clearance of these aggregates and
damaged organelles could be a possible therapeutic strategy in these dis-
eases (Banerjee et al., 2010). Autophagy and the ubiquitin-proteasome
system (UPS) are the major clearance pathways in the cell. Both systems
are responsible for the cellular homeostasis in eukaryotes and the preven-
tion of accumulation of abnormal proteins.While theUPS is indispensable
for the clearance of short-living proteins, the process of autophagy is im-
portant for the degradation of long-living proteins, abnormally folded
proteins and for organelle turnover (Nixon, 2013) (Fig. 1). Autophagy
subtypes differ in the way that the substrate to be degraded is delivered
to the lysosomes (Banerjee et al., 2010).Macroautophagy, further referred
to as autophagy, is themost studied subtype and it is characterized by the
formation of a double-bilayeredmembrane that encloses a portion of the
cytoplasm that contains the substrate that needs to be degraded. This re-
sults in the formation of a double-bilayered vesicle that is called the
autophagosome (Wong and Cuervo, 2010). In a later step of this process,
autophagosomes fuse with lysosomes to degrade their cargo. When two
essential genes for autophagy are ablated, mice develop a neurodegener-
ative phenotypewhich suggests an essential role of autophagy in neurons
(Hara et al., 2006; Komatsu et al., 2006).
An increased number of autophagosomes are present in motor
neurons of mutant SOD1 mice and sporadic ALS patients (Hetz et al.,
2009; Li et al., 2008;Morimoto et al., 2007; Tian et al., 2011). As autoph-
agy is a multistep process, it can get disrupted at many different levels
(Wong and Cuervo, 2010). Whether this is a causal event, a result due
to an upregulation of autophagy for the clearance of toxic proteins or
due to a disrupted autophagosome-lysosome fusion is still not clear.
Nevertheless, growing evidence suggests an overall impairment of
autophagy in ALS. Mutations in the SQSTM1 and UBQLN2 genes, both
involved in the regulation of autophagy, were discovered in sporadic
and familial patients (Deng et al., 2011; Fecto et al., 2011). Transfection
of cells with mutant UBQLN2 impaired autophagy, suggesting a loss of
functionmechanism for these mutations (Fecto et al., 2012). Moreover,
genetic stimulation of autophagy slowed down the disease progression
in ALSmice (Hetz et al., 2009). Different pharmacological approaches to
stimulate autophagy have been tested. Two independent studies
showed a negative effect on disease progression by treating mouse
models of ALS with rapamycin, which is an FDA-approved drug that in-
duces autophagy (Bhattacharya et al., 2012; Zhang et al., 2011). This
negative effect was probably due to the immunosuppressive function
of rapamycin, as the disease could be slowed down in immunodeﬁcient
ALS mice (Staats et al., 2013). These results show that it is important to
target autophagy with more speciﬁc compounds that do not have(negative) side-effects. Other compounds such as progesterone or tre-
halose, two activators of autophagy, have been administered to mutant
SOD1 mice and showed promising results, such as delayed disease
onset and longer survival which were correlated with an induction of
the autophagic ﬂux (Castillo et al., 2013; Kim et al., 2013; Zhang et al.,
2014). These data indicate that the modulation of autophagy can be a
potential therapeutic strategy for ALS.
Impaired axonal transport
Because of their long projections, neurons are highly dependent on
efﬁcient axonal transport mechanisms to bring proteins, organelles
and other cargoes to their sites of function or degradation.Microtubules
form tracks along axons onwhich numerous cargoes can be transported
with the help ofmotor proteins, which belong to the kinesin and the dy-
nein protein family (Fig. 1). These motor proteins hydrolyze ATP to
move their cargoes along the microtubules (De Vos et al., 2008). Since
axonal swellings containing neuroﬁlaments have been observed in spo-
radic and familial ALS patients (Okamoto et al., 1990; Sasaki and
Maruyama, 1992), axonal transport deﬁcits have been intensively stud-
ied in the context of ALS (reviewed in (De Vos et al., 2008)). In the mu-
tant SOD1 mouse model, defects in axonal transport are an early event
(Collard et al., 1995; De Vos et al., 2007; Kieran et al., 2005;
Williamson and Cleveland, 1999; Zhang et al., 1997). Moreover, point
mutations in the p150 subunit of the dynactin 1 (DCTN1) gene were
found in sporadic and familial ALS patients (Munch et al., 2004;
Stockmann et al., 2013). Dynactin stabilizes the binding of the cargo to
the motor protein dynein (Millecamps and Julien, 2013). Furthermore,
dynactin is necessary for the function of dynein (LaMonte et al., 2002).
The disruption of the dynein/dynactin complex through the selective
overexpression of a disassembler of dynactin in postnatal motor neu-
rons of mice caused late-onset progressive motor neuron degeneration
(LaMonte et al., 2002). A knockdown of the homologue of dynactin 1 in
a C. elegansmodel suggests that the observed motor neuron phenotype
is due to impaired autophagosome transport (Ikenaka et al., 2013). All
together, these results suggests an active contribution of axonal trans-
port deﬁcits in motor neuron degeneration and more speciﬁcally also
in ALS, as both the accumulation and site-speciﬁc loss of proteins, or-
ganelles and vesicles can lead to an aggravation of the phenotype. As a
consequence, attempts to improve axonal transport can be possible
therapeutic interventions (De Vos et al., 2008).
One possible strategy to reach this goal could be the use of
microtubule-modulating agents (Fanara et al., 2007; Jouroukhin et al.,
2013). In mutant SOD1 mice, microtubules are extremely unstable due
to enhanced microtubule dynamics (Fanara et al., 2007). When the as-
sembly/disassembly cycle is occurring at abnormally high rates, the
transport on this unstable road is severely impaired. Pharmacological
modulation of hyperdynamicmicrotubules inmutant SOD1mice recov-
ered axonal transport, increased the survival of motor neurons and had
a positive effect on the lifespan of the ALS mice (Fanara et al., 2007;
Jouroukhin et al., 2013).
A second strategy to improve axonal transport could be the en-
hancement of the α-tubulin acetylation. This approach has proven to
be successful in different disease models including a mouse model of
Charcot–Marie–Tooth disease (d'Ydewalle et al., 2011). Acetylation of
α-tubulin promotes the recruitment of the motor proteins kinesin-1
and dynein to the microtubules. Histone deacetylase 6 (HDAC6) is an
enzyme that can deacetylate α-tubulin, hence, inhibiting the function
of this enzyme could improve axonal transport. However, HDAC6 also
binds ubiquitin and enhances the microtubule transport mediated by
dynein of ubiquitinated proteins to the autophagy machinery in the
cell soma (Kawaguchi et al., 2003). As a consequence, a proper balance
of HDAC6 function is needed to maintain normal axonal transport and
to ensure the elimination of misfolded proteins in neurodegenerative
diseases. In themutant SOD1mousemodel, the beneﬁt on axonal trans-
port by inhibiting HDAC6 function seems to outweigh the hazardous
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cantly increased by genetic ablation of HDAC6 (Taes et al., 2013) or
pharmacological inhibition of HDACs (Yoo and Ko, 2011). These data
suggest a possible beneﬁcial effect on ALS progression by inhibition of
the deacetylating function of HDAC6. As a consequence, the develop-
ment and use of compounds selectively targeting the deacetylating
function of HDAC6 could have therapeutic potential.
Axon retraction
Studies in rodent models and post-mortem patient tissue showed
that axons from motor neurons can retract from the neuromuscular
junction long before the loss of cell bodies (Fischer et al., 2004; Frey
et al., 2000). When an axon retracts from the muscle, nerve sprouting
can occur in an attempt to form new compensatory connections.
Synapseswith low sprouting capacities aremore vulnerable to degener-
ation,while axonswith high sprouting capacity aremore resistant (Frey
et al., 2000). From a therapeutic point of view, axonal retraction could
be prevented by two different strategies: (1) induction of the sprouting
capacity of axons or (2) preservation of the stability and functionality of
neuromuscular junctions (Fig. 1).
Improving axonal sprouting capacity
One option to improve the sprouting capacity could be the reduction
of the inhibitory signals from the environment. Members of the netrin,
ephrin, slit and semaphorin family can mediate these negative signals
during axon guidance. A number of observations indicate that there is
a link between these systems and ALS. First, the expression of
the chemorepellent Semaphorin 3A (Sema3A) is induced in Schwann
cells at the synapses that are most vulnerable to degeneration in the
SOD1 model (De Winter et al., 2006). Moreover, a missense mutation in
the dihydropyrimidinase-like 3 (DPYSL3) or the collapsin responsemedi-
ator protein 4a (CRMP4) gene was associated with ALS in a French popu-
lation (Blasco et al., 2013). This protein mediates the effects of
semaphorins on axonal growth and neurite guidance (Blasco et al.,
2013). These observations suggest an active involvement of the inhibitory
system in mediating the axonal sprouting properties of neurons.
In the ephrin system, the EphA4 receptor was identiﬁed as an ALS
disease modiﬁer in zebraﬁsh, in rodent ALS models and in patients.
This receptor is highly expressed during development where it has an
axonal repellant function during the formation of the corticospinal
tract (Dottori et al., 1998) and the peripheral projections to the
hindlimbs (Eberhart et al., 2002). In adult life, general expression de-
creases but EphA4 can still have a major contribution in pathological
conditions (Goldshmit et al., 2004; Lemmens et al., 2013; Munro et al.,
2013; Van Hoecke et al., 2012). When EphA4 function was genetically
ablated or pharmacologically inhibited in mutant SOD1 rodent models,
disease onset and/or progression was slowed down. Moreover, the age
of onset and survival inversely correlated with mRNA expression levels
of EphA4 in blood of sporadic ALS patients (Van Hoecke et al., 2012).
Interestingly, EphA4 mRNA expression is highest in the large motor
neurons of the spinal cord, which are the most vulnerable ones in ALS
(Van Hoecke et al., 2012). When EphA4 is deleted in the SOD1 mouse,
the large motor neurons are protected. These data suggest a role for
EphA4 in determining the vulnerability of motor neurons for degenera-
tion in ALS. Moreover, the re-innervation of neuromuscular junctions
after sciatic nerve axotomy in mice lacking EphA4 is signiﬁcantly
increased, suggesting that EphA4 could modify the regeneration
capacity of motor axons (Van Hoecke et al., 2012). In conclusion,
targeting the ephrin system could be an interesting new therapeutic
strategy for ALS.
Preservation of neuromuscular junctions
Apart from enhancing the sprouting capacity of axons to reinnervate
muscles, preserving the integrity of the remaining neuromuscular
junctions can also delay axonal retraction and subsequent dysfunction.One approach could be to antagonize destabilizing proteins of the
neuromuscular junctions. Nogo-A plays such a role in ALS. There is
evidence that Nogo-A destabilizes the neuromuscular junctions during
ALS. Throughout development, Nogo-A is expressed by different neuron
types and is mainly localized in the growth cones of those with long
axons (Schwab, 2010). The expression of Nogo-A is lowered during
adult life. Interestingly, Nogo-A is upregulated in spinal cord andmuscle
of mutant SOD1 mouse models (Dupuis et al., 2002) and also in muscle
biopsies of ALS patients (Dupuis et al., 2002; Jokic et al., 2005). The
upregulation correlates with the severity of muscle atrophy and motor
function impairment in patients (Dupuis et al., 2002; Jokic et al.,
2005). When Nogo-A is deleted in the mutant SOD1 mouse, survival is
signiﬁcantly increased (Jokic et al., 2006). On the pathological level, de-
nervation of the neuromuscular junctions and motor neuron degenera-
tion were delayed. In contrast, overexpression of Nogo-A in muscle
ﬁbers of wild type mice destabilized neuromuscular junctions and
caused retraction of the nerve terminal (Jokic et al., 2006). This
suggests that the higher expression of Nogo-A detected in skeletal
muscle ﬁbers of ALS patients could affect the integrity of neuromuscular
junctions and that this could be followed by the destabilization and
retraction of the nerve ends. This could cause the retrograde axon
pathology that will result in the death of the motor neuron. Currently,
intravenous administration of an anti-Nogo-A antibody (Ozanezumab)
is in a Phase II clinical trial.
Translation of biological ﬁndings into new therapies
Despite all the recent insights into the molecular mechanism of the
disease, no improvement in the therapeutic options for ALS patients
has been obtained during the past 20 years. Only the effect of riluzole
has been conﬁrmed in different clinical trials (Bensimon et al., 1994,
2002; Lacomblez et al., 1996; Yanagisawa and Shindo, 1996). As indicat-
ed by a number of examples in this review, a large number of preclinical
studies have been performed in rodent models of ALS to prevent, re-
verse or modulate the disease process. So far, none of these therapeutic
strategies has been successfully replicated in clinical trials. As a conse-
quence, besides riluzole, only symptomatic treatments are applied to
improve the quality of life of ALS patients. Those treatments are based
on multidisciplinary care and also include the use of non-invasive ven-
tilation and early percutaneous endoscopic gastrostomy (Traynor et al.,
2003; Van Damme and Robberecht, 2009).
In this part of the review, we will discuss how the translational step
can be improved at the preclinical level.
Investigation of new pathogenic pathways
Recent discoveries in the ALS ﬁeld resulted in a paradigm shift,
which will have an important impact on the development of new
therapeutic strategies. It becomes more and more clear that many
genes linked to ALS encode for RNA/DNA binding proteins and/or
inﬂuence RNA metabolism. The identiﬁcation of mutations in genes
for TDP-43, FUS and C9ORF72 led to the idea that aberrant RNA
metabolism plays a crucial role in ALS pathogenesis (reviewed in
(Lemmens et al., 2010)). These insights shifted the focus from ‘ALS as
a proteinopathy’ to ‘ALS as a ribonucleopathy’ (Robberecht and
Philips, 2013).
A lot of attention is focused on TDP-43, as the protein is present in
ubiquitinated cytoplasmic neuronal inclusions in most patients with
ALS (Neumann et al., 2006). TDP-43 is mainly present in the nucleus
where it is involved in transcription, RNA splicing and micro-RNA
processing (Lee et al., 2012a). The protein can shuttle between the
nucleus and the cytoplasm. In the cytoplasm, TDP-43 is associated
with transport granules in which mRNA is transported to the sites of
translation (Fallini et al., 2012). In conditions of cellular stress, TDP-43
is incorporated in cytoplasmic stress granules until stress is resolved
(Dewey et al., 2011; McDonald et al., 2011). ALS-associated mutations
145L. Poppe et al. / Experimental Neurology 262 (2014) 138–151seem to induce a shift of TDP-43 from the nucleus to the cytoplasm,
where aggregates are formed (Johnson et al., 2009).
Like TDP-43, FUS is an RNA-binding protein involved in different
processes of RNA metabolism. It is mainly localized in the nucleus, but
it is also present in the cytoplasm and at postsynaptic densities (Aoki
et al., 2012; Zinszner et al., 1997). Most ALS-linked mutations disrupt
nuclear import, inducing the mislocalization of FUS in stress granules
and in inclusions (Dormann et al., 2010). These FUS-positive inclusions
are observed in brain and spinal cord of patients with FUS mutations
(Kwiatkowski et al., 2009; Vance et al., 2009).
Both TDP-43 and FUS target more than 5000 mRNAs
(Lagier-Tourenne et al., 2012; Polymenidou et al., 2011), which empha-
sizes their important role in normal cell functioning. However, it is still
a matter of debate whether the depletion of these proteins from the nu-
cleus (loss of function), the increased cytoplasmic aggregation
propensity (gain of function), or both are involved in disease pathogene-
sis (reviewed in (Lee et al., 2012a)). Screens for the detection ofmodiﬁers
of TDP-43 and FUS toxicity in cell systems, yeast and/or Drosophila, have
identiﬁed some modiﬁers of both TDP-43 and/or FUS toxicity, e.g.
ataxin-2 (ATXN2) and ‘debranching enzyme homologue 1’ (DBR1)
(Armakola et al., 2012; Elden et al., 2010).
In 2012, a major breakthrough in ALS genetics was the discovery of
hexanucleotide repeat expansions in the C9ORF72 gene as a common
cause of ALS (DeJesus-Hernandez et al., 2011; Renton et al., 2011). The
physiological function of the gene product is still unknown, but the
protein is structurally related to DENN proteins, which are GDP/GTP
exchange factors (GEFs) implicated in membrane trafﬁcking (Levine
et al., 2013). How these repeat expansions can cause ALS is intriguing
the ALS research ﬁeld. As C9ORF72mRNA levels are reduced in samples
of patients carrying the repeat expansion, a loss of function mechanism
is possible (DeJesus-Hernandez et al., 2011; Gijselinck et al., 2012). This
could be due to ineffective transcription of DNA carrying the repeat. In
contrast, repeat containing RNA foci in patients, suggest a deleterious
gain of function (DeJesus-Hernandez et al., 2011). Repeats are able to
form G-quadruplexes (Fratta et al., 2012; Reddy et al., 2013), which
may be able to facilitate the binding and sequestration of different
RNA binding proteins to the repeat (Lee et al., 2013). Subsequently,
these proteins are not able anymore to execute their normal functions.
A third mechanism is the possible occurrence of repeat-associated
non-ATG (RAN) translation along the hairpin-forming repeat. This re-
sults in aggregates containing different dipeptide repeat proteins
(DPRs) in patients with the C9ORF72 repeat expansion (Ash et al.,
2013; Gendron et al., 2013; Mori et al., 2013a, 2013b).
Before one can translate these ﬁndings into new causal or modifying
therapies, better insights into the exact pathogenic mechanisms are
essential. However, it is clear that these new insights in TDP-43, FUS
and C9ORF72 pathology will result in the development of a completely
new class of therapeutic strategies.Development of new disease models
The best currently available animal models of ALS are the mutant
SOD1 mouse and rat models that recapitulate the human disease pro-
cess. Hence, almost all preclinical research is performed using these
models. However, SOD1 mutations are only causing disease in approxi-
mately 20% of familial ALS patients and as a consequence this model is,
from a genetic point of view, only representative for about 2% of total
ALS patients. Thus, one should be cautious before translating experi-
mental ﬁndings from this model to humans, as the ALS patient popula-
tion is very heterogeneous and contains both sporadic and familial cases
with a wide range of different mutated genes. To enlarge the basis be-
fore starting a clinical trial, different models with different ALS-
causing mutations are needed. Moreover, these new models can also
provide us with more and better insights into the pathological mecha-
nism(s) caused by mutant TDP-43, FUS and C9ORF72.Although great efforts were made to obtain new rodent models, the
generated ones do not represent the progressive neurodegeneration
and pathology observed in the human disease so far (McGoldrick
et al., 2013). While waiting for new rodent models, alternative model
organisms such as yeast, Drosophila and zebraﬁsh can be used (Elden
et al., 2010; Lemmens et al., 2007). These alternative model organisms
have the additional advantage in comparison to rodent models that
more therapeutic approaches can be screened (Giacomotto and
Segalat, 2010; Lemmens et al., 2007).
Besides model organisms, human iPSCs give the opportunity to
develop cultured human neuronal cells carrying different disease-
causing mutations, partially representing the genetic variability
occurring in patients. These are adult pluripotent stem cells generated
from somatic cells by the overexpression of different reprogramming/
transcription factors, and can be forced to differentiate into different
cell types by the use of speciﬁc growth factors and cell culture condi-
tions (Dolmetsch and Geschwind, 2011). IPSCs from patients with
different disease-causing mutations have already been developed,
which include mutations in the SOD1, vesicle-associated membrane
protein-associated protein B/C (VAPB), TDP-43 and C9ORF72 genes
(Almeida et al., 2013; Bilican et al., 2012; Dimos et al., 2008; Donnelly
et al., 2013; Egawa et al., 2012; Sareen et al., 2013; Zhang et al.,
2013b). Moreover, iPSC-derived motor neurons from sporadic patients
with TDP-43 pathology have also been obtained (Burkhardt et al.,
2013). Although iPSC-derived neurons give the opportunity to study
human-derived neuronal cells, they cannot replace whole-organism
models as these cells lack the anatomical and biological context. One
way to (partially) overcome this problem is to perform studies on
mixed cell cultures containing different cell types.Reproducibility of experiments in rodent models
One problem to translate preclinical ﬁndings into new treatments
for patients is the lack of reproducibility of the preclinical studies. Re-
cently, the ALS Therapy Development Institute (TDI) retested different
compounds with a reported beneﬁcial effect in the mutant SOD1
mousemodel. Unfortunately, TDIwas unable to obtain any beneﬁcial ef-
fect (Perrin, 2014). As this was not the ﬁrst study in which a positive ef-
fect could not be reproduced (Scott et al., 2008), it is extremely
important to improve the robustness of preclinical studies.
Standardized protocols should be followed in order to improve the
comparability between different laboratories of the outcome of a treat-
ment. Consensus guidelines have beenwritten in order to avoid the lack
of reproducibility (Ludolph et al., 2010) and should be conscientiously
followed. These guidelines include the description of measurements to
determine onset, disease progression and end stage. These different
parameters should be always measured to determine whether a thera-
peutic approach successfully modulates the disease process. More than
one technique should be used to assess onset and disease progression
and if there is a positive outcome it should be accompanied by a
histological assessment. Motor neuron counts in the spinal cord and
evaluation of the neuromuscular junction integrity are important to in-
terpret the positive effect of a potential therapy. Moreover, performing
the preclinical studies by an experimenter blinded for the treatment
condition and using always the proper controls (age- and gender-
matched) will also increase the robustness of the experimental
outcome.
Phenotypic variability could be another source for the lack of repro-
ducibility. One important reason for this variability is the unstable
inheritance of the number of overexpressed SOD1 copies, as this is an
important determinant of disease onset and life span. As a consequence,
quantiﬁcation of the number of SOD1 gene copies by quantitative PCR
(qPCR) and/or a rigorous follow-up of the life span of the transgenic
breeders is important to maintain a homogeneous cohort without
copy number loss.
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the characteristics of the mouse cohort that was used in a preclinical
study is crucial to interpret the validity of any published preclinical
study.
Optimization of the experimental design
A proper design of a preclinical experiment is of great importance to
predict the translational potential of a therapeutic approach.
First, the number of animals in an experimental group should be
sufﬁcient to overcome the intrinsic phenotypic variability. In order to
limit this variation, littermate controls should be used. In order to
estimate the number of animals needed, a statistical power calculation
based on the expected variability and the predicted therapeutic effect
should be performed.
Second, the pharmacokinetics of the compound should be deter-
mined in order to estimate the proper dose of the drug. Moreover, it is
very important to check whether the drug is reaching the target tissue.
Third, the treatment strategy of a compound in a rodent model
should resemble as much as possible the situation in the clinic. The
time point and the mode of administration are the two most important
parameters in relation to this issue. In preclinical experiments, treat-
ment is most often started before the phenotypic onset of the disease.
This is not a feasible therapeutic strategy for sporadic ALS patients. As
a consequence, it is important that the administration of a compound
in a preclinical trial is also performed at an age that is closer to onset
or even after the onset of symptoms.
Finally, themode of administration should be chosen based on the in-
trinsic properties of the compound. Asmany compounds have lowblood-
brain barrier permeability or can induce peripheral side effects, the classi-
cal administration by intraperitoneal injections or oral gavage is not al-
ways the most optimal one. In these cases, alternative delivery
strategies should be considered. These alternative strategies have been
extensively and successfully explored in mutant SOD1 rodent models
for the administration of neurotrophic factors. Administration of neuro-
trophic factors intrathecally, intracerebroventricularly, in speciﬁc areas
of the spinal cord or in themuscle leads to the preservation ofmotor neu-
rons and/or axonal integrity in ALS rodent models and to an attenuation
of the disease process (Acsadi et al., 2002; Azzouz et al., 2004;
Dobrowolny et al., 2005; Dodge et al., 2010; Franz et al., 2009; Hwang
et al., 2009; Kaspar et al., 2003; Lepore et al., 2007; Nagano et al., 2005;
Park et al., 2009; Storkebaum et al., 2005; Suzuki et al., 2007, 2008).
Validation and amelioration of the therapeutic target
Whenever a possible therapeutic target is discovered, the molecular
mechanism(s) by which the therapeutic effect is caused should be in-
vestigated. This will not only generate new insights into the disease
mechanism(s) but also increase the number of possible therapeutic tar-
gets. It could be easier to develop compounds for another target within
the same pathwaymodulating the same pathogenic process as the orig-
inal one (e.g. targeting an enzyme versus a structural protein) or itmight
be possible that better compounds directed against these new targets
already exist.
Conclusions
During the last decade, the knowledge about the biological mecha-
nisms that could be involved in ALS has substantially improved. Both
additional causal genes and new pathological processes underlying
the selective motor neuron death were identiﬁed. Developing a causal
therapy that targets a speciﬁc disease-causing gene can have a huge
effect by preventing the pathological events responsible for the disease.
However, only a limited number of patients affected by ALS will beneﬁt
from this therapy. The alternative approach is to target pathogenic
processes such as astrocytosis, neuroinﬂammation, mitochondrialdysfunction, deregulated autophagy, and/or axonal transport dysfunc-
tion and retraction that commonly arise in patients with different ALS
etiologies. Most likely, the effect of such a modifying treatment will be
smaller compared to that of a causal treatment, but the target popula-
tion will be larger as all ALS patients could beneﬁt from this treatment.
In order to achieve a more prominent effect, different modifying thera-
pies could be combined in order to have an additive and hopefully even
a synergistic effect.
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